2-(3,5-dimethoxyphenyl)furan | 1333472-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3,5-dimethoxyphenyl)furan
• CAS: 1333472-77-7
• 化学式: C₁₂H₁₂O₃
• 分子量: 204.225
• InChiKey: ADJXFJVZGUSTKS-UHFFFAOYSA-N

物化性质

• 沸点：
  298.6±25.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  31.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3,5-dimethoxyphenyl)furan 在 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors

  摘要：

  Based on perlolyrine (1), a natural alkaloid with weak PDE5 potency from the traditional Chinese aphrodisiac plant Tribulus terrestris L., a series alpha-substituted tetrahydro-beta-carboline (TH beta C) derivatives were synthesized via T(+)BF4(-)-mediated oxidative C-H functionalization of N-aryl TH beta Cs with diverse potassium trifluoroborates. Following Winterfeldt oxidation afforded the corresponding furyl/thienyl pyrroloquinolones, of which 5-ethylthiophene/ethylfuran derivatives 20a-b were identified as the most potent and selective PDE5 inhibitors. Among the enantiomers, (S)-20a and (S)-20b (IC50 = 0.52 and 0.39 nM) were found to be more effective than their (R)-antipode, display favorable pharmacokinetic profiles, exert in vitro vasorelaxant effects on the isolated thoracic aorta, and exhibit in vivo efficacy in the anesthetized rabbit erectile model. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.02.039
• 作为产物：
  描述：

  3,5-二甲氧基苯胺 在 tetrafluoroboric acid 、 溶剂红 43 、 sodium nitrite 作用下， 以 水 、 二甲基亚砜 为溶剂， 生成 2-(3,5-dimethoxyphenyl)furan
  参考文献：
  名称：

  重氮盐的可见光致敏光接枝。

  摘要：

  在光敏剂（Ru（bipy）3 2+或曙红Y）的存在下，浸入不同取代的芳基重氮盐溶液中的金表面的可见辐照导致所连接的芳基对表面的修饰。获得接枝的纳米厚的聚苯撑膜。反应扩展到聚氯乙烯（PVC）表面。提出的用于形成该膜的机理涉及形成芳基，该芳基与表面然后与第一接枝的芳基反应。该膜的特征在于红外反射吸收光谱法（IRRAS），X射线光电子能谱法（XPS），水接触角和椭圆光度法。

  DOI：

  10.1021/cm3032994

文献信息

• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Cutshall Neil S.

  公开号：US20110224202A1

  公开（公告）日：2011-09-15

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

  揭示了抑制PDE10的化合物，对治疗多种疾病有用，包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病，如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动综合征、精神分裂症、妄想症、药物诱发的精神病、恐慌和强迫症。还提供了这些化合物的药用盐、立体异构体、溶剂合物和前药。还揭示了含有化合物与药用载体组合的组合物，以及与使用有关的方法，用于在需要的温血动物中抑制PDE10。
• PDE10 inhibitors and related compositions and methods
  申请人：Omeros Corporation

  公开号：US08343970B2

  公开（公告）日：2013-01-01

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

  本文披露了抑制PDE10的化合物，具有治疗多种疾病的效用，包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病，如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑性瘫痪、睡眠障碍、疼痛、抽动症、精神分裂症、妄想性障碍、药物诱导的精神病、恐慌和强迫症。此外，还提供了该化合物的药物可接受的盐、立体异构体、溶剂化物和前药。还披露了含有化合物和药物可接受的载体的组合物，以及与之相关的方法，用于抑制需要同样的温血动物中的PDE10。
• US8343970B2
  申请人：——

  公开号：US8343970B2

  公开（公告）日：2013-01-01
• US9102643B2
  申请人：——

  公开号：US9102643B2

  公开（公告）日：2015-08-11
• US9434707B2
  申请人：——

  公开号：US9434707B2

  公开（公告）日：2016-09-06